Morphometry was applied to quantitate characteristic microscopical features of the removed non invasive papillary bladder tumours in 60 patients and of the normal urothelium in 13 cases. The measurements of nuclear areas were made on routine HES section with a microscopic digitiser (ASM-Leitz). There was a significant difference, concerning the average nuclear area, between normal urothelium and bladder tumours and also a correlation between the number of relapses at two years and this parameter. A significant difference existed for the average nuclear area of tumour without any relapse and the tumours with one or several relapses (p less than 0,02). A difference existed also between the tumours that caused cystectomie or early death and other tumours (p less than 0,01). The anisocaryosis (evaluated by the mean of the coefficient of variation of the average nuclear area) was greater in cases of tumours with bad prognosis (death). These results confirm the prognostic value of morphometric parameters in the histological analysis of papillary bladder tumours.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
URINARY BLADDER PARAGANGLIOMA- A NOTEWORTHY, RARE ENTITY.
Acta Endocrinol (Buchar)
January 2025
All India Institute of Medical Science, Department of Pathology & Lab Medicine, Mangalagiri, Guntur, India.
Unlabelled: Urinary Bladder paraganglioma accounts for 0.06% of all bladder tumors and 1% of all pheochromocytoma. Most tumors are localized at the dome or trigone and are unifocal.
View Article and Find Full Text PDFBacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol.
Syst Rev
January 2025
Department of Medicine, Division of Infectious Diseases, Duke University, 148 Hanes House, 315 Trent Dr, Durham, NC, 27710, USA.
Background: Although intravesical Bacillus Calmette-Guerin (BCG) immunotherapy usually exhibits a favorable safety profile, it can lead to the development of BCG infections, both localized and disseminated. Understanding of BCG infections following intravesical BCG immunotherapy is limited because of the lack of consensus definitions of BCG infections and limited post-instillation follow-up. We aim to perform a systematic review of the literature of BCG infections following intravesical BCG immunotherapy to elucidate the epidemiology, risk factors, and outcomes of BCG infections.
View Article and Find Full Text PDFEthnicity and race as modifiers of the association between patient sex and stage at diagnosis of bladder cancer.
Cancer Epidemiol
January 2025
Florida International University Herbert Wertheim College of Medicine, Miami, FL, USA. Electronic address:
Background: With over 80,000 projected new diagnoses in 2024, bladder cancer remains a significant public health concern. Given the absence of routine screening protocols, identifying high-risk populations becomes crucial for early detection and intervention. This study aimed to investigate whether race and ethnicity modify the association between sex and stage at diagnosis in adults with primary bladder cancer.
View Article and Find Full Text PDFCombining a Risk Factor Score Designed From Electronic Health Records With a Digital Cytology Image Scoring System to Improve Bladder Cancer Detection: Proof-of-Concept Study.
J Med Internet Res
January 2025
Univ Rennes, CHU Rennes, INSERM, LTSI - UMR 1099, F-35000 Rennes, France.
Background: To reduce the mortality related to bladder cancer, efforts need to be concentrated on early detection of the disease for more effective therapeutic intervention. Strong risk factors (eg, smoking status, age, professional exposure) have been identified, and some diagnostic tools (eg, by way of cystoscopy) have been proposed. However, to date, no fully satisfactory (noninvasive, inexpensive, high-performance) solution for widespread deployment has been proposed.
View Article and Find Full Text PDFReanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.
JAMA Netw Open
January 2025
Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel.
Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!